Perioperative Chemotherapy, a New Approach to Pancreatic Cancer: An Interview With Alice C. Wei, MD, MSc

The most common type of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC) has limited treatment options and a low survival rate. Traditionally, patients whose disease is resectable—able to be removed by surgery—have been treated with a post-operative adjuvant approach, consisting of surgery followed by chemotherapy or radiation. In recent years, however, there has been a heightened interest in perioperative treatment, in which patients receive chemotherapy or radiation both before and a...
Continue reading

Treating Triple-Class Refractory Myeloma With Ajai Chari, MD

​With increasing frequency, multiple myeloma is becoming triple-class refractory, or refractory to all three primary classes of drugs used in its treatment. What is to be done in such cases? In the phase 2b STORM study, now published in The New England Journal of Medicine, Ajai Chari, MD, and colleagues report that a combination of oral selinexor and dexamethasone shows efficacy in patients with triple-class refractory disease. In this interview with i3 Health, Dr. Chari discusses the importance...
Continue reading

Treating Cisplatin-Ineligible Metastatic Urothelial Carcinoma: Sarmad Sadeghi, MD, PhD

For many patients with metastatic urothelial carcinoma, cisplatin-containing chemotherapy is not an option; alternative treatments are greatly needed. Recently, the phase 2 California Cancer Consortium trial, led by Sarmad Sadeghi, MD, PhD, reported that a combined regimen of gemcitabine (Gemzar®, Eli Lilly) and eribulin (Halaven®, Eisai Inc.) demonstrates efficacy in cisplatin-ineligible patients with metastatic urothelial carcinoma. In this interview with i3 Health, Dr. Sadeghi discusses the i...
Continue reading

Adavosertib (AZD1775) with Gemcitabine and Radiation for Locally Advanced Pancreatic Cancer: An Interview With Kyle C. Cuneo, MD

Pancreatic cancer is one of the most aggressive forms of cancer, and owing to limited treatment options, it has one of the lowest survival rates. While patients are commonly treated with radiation therapy, there is a need to develop alternative treatment options that can improve the efficacy of radiation, reduce tumor progression, and increase survival. In a recent study, Kyle C. Cuneo, MD, and colleagues evaluated the safety and tolerability of adavosertib (AZD1775), an inhibitor of the Wee1 ki...
Continue reading

Congenital Heart Disease Linked to Cancer: Interview With Zacharias Mandalenakis, MD, PhD

One of the most common birth defects, congenital heart disease (CHD) is associated with an increased risk of developing cancer. Zacharias Mandalenakis, MD and colleagues conducted a study to further explore the link between CHD and cancer. In this interview with i3 Health, Dr. Mandalenakis provides insights on this link and strategies for mitigating risk. What led you to research this topic?Zacharias Mandalenakis, MD, PhD: I am an adult cardiologist, and I work at the Adult Congenital Heart Asso...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.